Brief: Kyowa Kirin Announces First Patient Enrolled In The Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops In Patients With Diabetic Macular Edema
06/02/2024 12:20
Feb 6 (Reuters) - Kyowa Kirin Co Ltd 4151.T :
* KYOWA KIRIN ANNOUNCES FIRST PATIENT ENROLLED IN THE PHASE
2
CLINICAL TRIAL EVALUATING TIVOZANIB EYE DROPS IN PATIENTS WITH
DIABETIC MACULAR EDEMA
* KYOWA KIRIN CO LTD: PHASE 2 STUDY WILL BE RECRUITING 150
PATIENTS WITH DME ACROSS US, JAPAN, AUSTRALIA AND SOUTH KOREA
* KYOWA KIRIN CO LTD: SEPARATE PHASE 2 STUDY TO EVALUATE
KHK4951
IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IS
ALSO BEING INITIATED
Source text for Eikon: ID:nPn6dsCPWa
Further company coverage: 4151.T
Recent news on Kyowa Kirin
See all newsFactbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Kyowa Kirin Announces Agreement With US Administration To Reduce Treatment Costs For Americans
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia